+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liquid Biopsy Market - Global Forecast 2026-2032- Product Image
Liquid Biopsy Market - Global Forecast 2026-2032- Product Image
Sale

Liquid Biopsy Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904966
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liquid Biopsy Market is projected to reach USD 8.44 Billion in 2026. It is expected to continue growing at a CAGR of 12.63%, reaching USD 17.31 Billion by 2032.

Liquid biopsy is redefining precision oncology by enabling analysis of circulating tumor DNA, circulating tumor cells, cell-free DNA, RNA, methylation signatures, exosomes, and other analytes from blood or other body fluids. Unlike conventional tissue biopsy, liquid biopsy can support less invasive sampling, longitudinal monitoring, and faster molecular profiling when tissue is unavailable, insufficient, or difficult to access.

The field has moved from exploratory research to clinical utility, supported by U.S. FDA-authorized companion diagnostics, broad use of next-generation sequencing, and increasing guideline recognition in advanced cancers. Demand is strongest in therapy selection, resistance monitoring, minimal residual disease assessment, recurrence surveillance, and emerging multi-cancer early detection applications, where evidence quality, analytical sensitivity, and clinical validity remain decisive adoption factors.

Transformative Shifts in Liquid Biopsy

The liquid biopsy landscape is shifting from single-gene mutation testing toward broader multi-analyte, multi-omics platforms. Laboratories and diagnostics developers are combining ctDNA mutation profiling with methylation, fragmentomics, epigenomic signals, proteomics, and AI-enabled interpretation to improve sensitivity and clinical relevance across cancer stages.

Regulatory and reimbursement expectations are also transforming adoption. FDA-cleared and FDA-approved tests have strengthened physician confidence, while payers increasingly require evidence of clinical utility, outcome improvement, and cost-effectiveness. At the same time, decentralized blood collection, biopharma partnerships, and clinical trial stratification are expanding use beyond late-stage oncology into recurrence risk, treatment response, and screening, particularly in settings where repeat tissue biopsy is clinically impractical.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the impact of liquid biopsy by improving signal detection in low-abundance tumor fractions, reducing sequencing noise, and supporting interpretation of complex genomic and epigenomic patterns. Machine learning models are increasingly used for variant calling, methylation classification, tumor-origin prediction, and risk stratification, especially where early-stage disease produces limited ctDNA.

AI also supports operational scalability through automated quality control, bioinformatics workflow optimization, laboratory workflow prioritization, and clinical decision support. However, adoption depends on transparent validation, bias assessment across populations, data governance, cybersecurity, and compliance with evolving AI and medical device regulations. The most defensible AI-enabled liquid biopsy strategies are those anchored in prospective clinical evidence, reproducible model performance, and traceable analytical validation.

Key Regional Insights: Global Liquid Biopsy Adoption

North America remains a leading liquid biopsy region due to advanced oncology infrastructure, established molecular pathology networks, FDA regulatory pathways, major clinical trial activity, and payer engagement around companion diagnostics and genomic profiling. The United States anchors adoption through precision medicine programs, cancer center networks, and integration of liquid biopsy into oncology drug development, while Canada shows steady implementation through provincial oncology systems, centralized laboratory models, and evidence-based reimbursement review.

Europe is shaped by strong academic oncology, the EU In Vitro Diagnostic Regulation, and national health technology assessment processes that emphasize clinical validity, clinical utility, and quality management. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in genomic medicine, local sequencing capacity, cancer screening infrastructure, and advanced oncology care. Latin America is progressing through private-sector testing, reference-lab partnerships, and expanding molecular oncology awareness, while the Middle East is accelerating precision oncology through national transformation programs, advanced hospital systems, and investment in genomic medicine. Africa remains earlier in adoption, with opportunities centered on access, sample logistics, oncology workforce development, laboratory accreditation, and regional reference laboratories that can improve availability of liquid biopsy testing.

Key Group Insights: Strategic Liquid Biopsy Clusters

Within ASEAN, liquid biopsy demand is supported by rising cancer burden, medical tourism hubs, expanding private diagnostics networks, and improving access to oncology specialists, although reimbursement, laboratory standardization, and cross-country regulatory alignment remain uneven. The GCC is investing in precision medicine, population health, advanced oncology centers, and digital health infrastructure, creating favorable conditions for premium liquid biopsy services, localized validation, and partnerships with diagnostic providers and academic hospitals.

The European Union is defined by IVDR compliance, cross-border cancer research, quality assurance requirements, and evidence-led reimbursement, making analytical validation and demonstrated clinical utility essential for scale. BRICS countries are important growth engines because of large patient populations, local sequencing capabilities, government interest in biotechnology self-sufficiency, and expanding cancer care capacity. G7 markets lead in clinical trial adoption, regulatory sophistication, reimbursement scrutiny, and oncology guideline integration, while NATO countries benefit from overlapping healthcare modernization, biomedical research funding, laboratory interoperability initiatives, and secure data infrastructure that can strengthen genomic medicine and liquid biopsy implementation.

Key Country Insights: Priority Liquid Biopsy Markets

The United States leads commercialization through FDA-authorized assays, companion diagnostic use, oncology guideline adoption, and biopharma use in clinical trials. Canada is advancing through centralized cancer programs, provincial testing pathways, and evidence-based assessment, while Mexico and Brazil show growing private-lab adoption, reference laboratory partnerships, and increasing interest in expanding molecular oncology access. The United Kingdom, Germany, France, Italy, and Spain are building liquid biopsy use through national genomics strategies, cancer networks, molecular tumor boards, and health technology assessment discipline; Russia’s market is shaped by domestic testing capacity, regional oncology infrastructure, and constrained access to some international technologies.

China is scaling local liquid biopsy innovation through high-volume oncology demand, domestic sequencing capacity, and regulatory attention to advanced diagnostics. India is expanding access through urban oncology centers, cost-sensitive laboratory models, and rising demand for precision cancer care. Japan and South Korea benefit from strong precision medicine ecosystems, regulatory maturity, advanced cancer care infrastructure, and active oncology research networks. Australia supports adoption through guideline-driven oncology practice, academic research, established molecular pathology networks, and structured evaluation of new diagnostic technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications with clear clinical utility, such as therapy selection in advanced cancer, resistance monitoring, and measurable residual disease programs backed by prospective evidence. Product roadmaps should align assay performance with intended use, including limits of detection, tumor fraction requirements, sample handling specifications, turnaround time, reporting clarity, and interpretability for oncologists.

Commercial success will depend on payer-ready evidence, regulatory-quality validation, laboratory accreditation, and partnerships with cancer centers, biopharma sponsors, and reference laboratories. Organizations should invest in interoperable bioinformatics, transparent AI governance, diverse clinical datasets, real-world evidence generation, and patient-friendly blood collection models. Regional strategies should be tailored to reimbursement maturity, oncology infrastructure, local regulatory requirements, and clinical workflow readiness rather than relying on one global commercialization template.

Research Methodology

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and industry-recognized sources. Inputs include regulatory databases and announcements from agencies such as the U.S. FDA and European authorities; clinical guidance from oncology organizations including NCCN, ASCO, and ESMO; peer-reviewed oncology and molecular diagnostics literature; clinical trial registries; reimbursement updates; public health datasets from sources such as WHO and OECD; and documented technology developments in next-generation sequencing, ctDNA analysis, methylation profiling, and AI-enabled bioinformatics.

Insights are triangulated across regulatory milestones, clinical adoption signals, technology trends, regional healthcare infrastructure, guideline evolution, reimbursement conditions, and peer-reviewed evidence. The analysis excludes unsupported market claims and emphasizes evidence-backed interpretation of liquid biopsy applications, including companion diagnostics, ctDNA profiling, minimal residual disease, recurrence monitoring, treatment response assessment, and early detection research.

Conclusion: Evidence-Led Growth in Liquid Biopsy

Liquid biopsy has become a central pillar of precision oncology because it offers a practical route to real-time molecular insight with lower procedural burden than tissue biopsy. Its strongest current value lies in therapy selection, resistance detection, and longitudinal monitoring, while early cancer detection and multi-cancer screening remain high-potential areas requiring rigorous validation, careful implementation, and clear evidence of clinical benefit.

The next phase of leadership will be defined by clinical evidence, regulatory credibility, AI-enabled analytical performance, reimbursement alignment, and equitable access. Organizations that combine scientifically validated assays with payer-aligned outcomes, regional execution, robust laboratory quality systems, and trustworthy data infrastructure will be best positioned to shape the future of liquid biopsy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Liquid Biopsy Market, by Biomarkers
7.1. Introduction
7.2. Cell-free DNA
7.3. Circulating Tumor Cells
7.4. Circulating Tumor DNA
7.5. Extracellular Vesicles
8. Liquid Biopsy Market, by Sample
8.1. Introduction
8.2. Blood Based
8.3. Urine Based
9. Liquid Biopsy Market, by Type
9.1. Introduction
9.2. Assay Kits
9.3. Instruments
9.4. Services
10. Liquid Biopsy Market, by Technology
10.1. Introduction
10.2. Multi-gene Parallel Analysis using NGS
10.3. Single-gene Analysis using PCR Microarrays
11. Liquid Biopsy Market, by Indication
11.1. Introduction
11.2. Cancer Indication
11.2.1. Breast Cancer
11.2.2. Colorectal Cancer
11.2.3. Lung Cancer
11.2.4. Melanoma
11.2.5. Prostate Cancer
11.3. Non-Cancer Indication
12. Liquid Biopsy Market, by End-User
12.1. Introduction
12.2. Academic & Research Centers
12.3. Clinical Diagnostic Laboratories
12.4. Hospitals
12.5. Physician’s Office Laboratories
13. Liquid Biopsy Market, by Application
13.1. Introduction
13.2. Early Cancer Screening
13.3. Recurrence Monitoring
13.4. Therapy Selection
13.5. Treatment Monitoring
14. Liquid Biopsy Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Liquid Biopsy Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Liquid Biopsy Market, by Country
16.1. United States
16.2. China
16.3. Germany
16.4. Japan
16.5. Canada
16.6. United Kingdom
16.7. France
16.8. Australia
16.9. Russia
16.10. India
16.11. Italy
16.12. Mexico
16.13. Brazil
16.14. Spain
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. ANGLE PLC
18.2. Bio-Rad Laboratories, Inc.
18.3. Bio-Techne Corporation
18.4. Biocartis NV
18.5. Danaher Corporation
18.6. DiaCarta, Inc.
18.7. Dxcover Limited
18.8. Epic Sciences Inc.
18.9. Exact Sciences Corporation
18.10. F. Hoffmann-La Roche Ltd.
18.11. GENCURIX
18.12. Guardant Health, Inc.
18.13. Illumina, Inc.
18.14. Labcorp Holdings Inc.
18.15. Laboratory Dr. med. Pachmann
18.16. Lucence Health Inc.
18.17. LungLife AI, Inc.
18.18. MDxHealth SA
18.19. Menarini Silicon Biosystems SpA
18.20. Merck KGaA
18.21. Myriad Genetics, Inc.
18.22. Natera, Inc.
18.23. NeoGenomics Laboratories, Inc.
18.24. OncoDNA SA
18.25. PerkinElmer, Inc.
18.26. Personalis, Inc.
18.27. QIAGEN N.V.
18.28. SAGA Diagnostics AB
18.29. Strand Life Sciences Pvt Ltd.
18.30. Sysmex Corporation
18.31. Tempus AI, Inc.
18.32. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL LIQUID BIOPSY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LIQUID BIOPSY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LIQUID BIOPSY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LIQUID BIOPSY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CELL-FREE DNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CELL-FREE DNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CELL-FREE DNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL EXTRACELLULAR VESICLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL EXTRACELLULAR VESICLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL EXTRACELLULAR VESICLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BLOOD BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BLOOD BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BLOOD BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL URINE BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL URINE BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL URINE BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ASSAY KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ASSAY KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ASSAY KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MULTI-GENE PARALLEL ANALYSIS USING NGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MULTI-GENE PARALLEL ANALYSIS USING NGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MULTI-GENE PARALLEL ANALYSIS USING NGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SINGLE-GENE ANALYSIS USING PCR MICROARRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SINGLE-GENE ANALYSIS USING PCR MICROARRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SINGLE-GENE ANALYSIS USING PCR MICROARRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CANCER INDICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CANCER INDICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CANCER INDICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL NON-CANCER INDICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL NON-CANCER INDICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL NON-CANCER INDICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PHYSICIAN’S OFFICE LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PHYSICIAN’S OFFICE LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PHYSICIAN’S OFFICE LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL THERAPY SELECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL THERAPY SELECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL THERAPY SELECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 116. EUROPE LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. EUROPE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 118. EUROPE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 119. EUROPE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 120. EUROPE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 121. EUROPE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 122. EUROPE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 123. EUROPE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 124. EUROPE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 134. AFRICA LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 136. AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 137. AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 138. AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 139. AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 140. AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 142. AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. ASEAN LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. ASEAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 146. ASEAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 147. ASEAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 148. ASEAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 149. ASEAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 150. ASEAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 151. ASEAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 152. ASEAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 153. GCC LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GCC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 155. GCC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 156. GCC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 157. GCC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 158. GCC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 159. GCC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 160. GCC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 161. GCC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 171. BRICS LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. BRICS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 173. BRICS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 174. BRICS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 175. BRICS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 176. BRICS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 177. BRICS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 178. BRICS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 179. BRICS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 180. G7 LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. G7 LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 182. G7 LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 183. G7 LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 184. G7 LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 185. G7 LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 186. G7 LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 187. G7 LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 188. G7 LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 189. NATO LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 190. NATO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 191. NATO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 192. NATO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 193. NATO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 194. NATO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 195. NATO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 196. NATO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 197. NATO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 198. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 208. CHINA LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 209. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 210. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 211. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 212. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 213. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 214. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 215. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 216. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 217. GERMANY LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 218. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 219. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 220. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 221. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 222. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 223. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 224. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 225. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 226. JAPAN LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. JAPAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 228. JAPAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 229. JAPAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 230. JAPAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 231. JAPAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 232. JAPAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 233. JAPAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 234. JAPAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 235. CANADA LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 237. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 238. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 239. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 240. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 241. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 242. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 243. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 253. FRANCE LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 254. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 255. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 256. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 257. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 258. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 259. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 260. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 261. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. AUSTRALIA LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 264. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 265. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 266. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 267. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 268. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 269. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 270. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 271. RUSSIA LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 273. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 274. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 275. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 280. INDIA LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 281. INDIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 282. INDIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 283. INDIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 284. INDIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 285. INDIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 286. INDIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 287. INDIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 288. INDIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 289. ITALY LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 291. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 292. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 293. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 294. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 295. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 296. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 297. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 298. MEXICO LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 299. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 300. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 301. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 302. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 303. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 304. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 305. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 306. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 316. SPAIN LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 317. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 318. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 319. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 320. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 321. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 322. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 323. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 324. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 325. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 326. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 327. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2017-2032 (USD MILLION)
TABLE 328. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 329. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 330. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 331. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2017-2032 (USD MILLION)
TABLE 332. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 333. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 334. GLOBAL LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 335. GLOBAL LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • ANGLE PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis NV
  • Danaher Corporation
  • DiaCarta, Inc.
  • Dxcover Limited
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENCURIX
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Dr. med. Pachmann
  • Lucence Health Inc.
  • LungLife AI, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • QIAGEN N.V.
  • SAGA Diagnostics AB
  • Strand Life Sciences Pvt Ltd.
  • Sysmex Corporation
  • Tempus AI, Inc.
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.44 Billion
Forecasted Market Value ( USD ) by 2032 $ 17.31 Billion
Compound Annual Growth Rate12.6%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032 - Product Image

Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Cancer Biomarkers Market - Global Forecast 2026-2032 - Product Image

Cancer Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Liquid Biopsy Market (5th Edition) by Type of Technology, Type of Sample, Type of Circulating Biomarker, Type of Cancer, Application, End-user and Geographical Regions - Trends and Global Forecasts, 2026-2035 - Product Image

Liquid Biopsy Market (5th Edition) by Type of Technology, Type of Sample, Type of Circulating Biomarker, Type of Cancer, Application, End-user and Geographical Regions - Trends and Global Forecasts, 2026-2035

  • Report
  • 403 Pages
  • Global
From
Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker, Technology, Sample Type, Application, Clinical Application, End Use, Product, Region, and Segment Forecasts, 2026-2033 - Product Image

Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker, Technology, Sample Type, Application, Clinical Application, End Use, Product, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Liquid Biopsy Market Report by Product And Service, Circulating Biomarker, Cancer Type, End User, and Region 2026-2034 - Product Image

Liquid Biopsy Market Report by Product And Service, Circulating Biomarker, Cancer Type, End User, and Region 2026-2034

  • Report
  • 138 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.